File 04 - dosing on the record
Thymosin Alpha-1 dosage, as it appears in the studies - reported by population and route, never as a personal instruction.
What was administered to whom, by which route, for how long. Research data only.
The short version
Here is the plain version of Thymosin Alpha-1 dosage before the specifics. This is research data, not a how-to. Nothing on this page tells you to take anything; it reports what was given to patients in studies, by whom and how. The peptide is given as a subcutaneous (under-the-skin) injection in essentially every trial. The most common regimen studied for chronic hepatitis is a small fixed dose given twice a week. Sepsis trials used a larger, more frequent schedule for about a week. The drug clears from the blood fairly quickly - a half-life of roughly two hours - so it does not linger. Because it is not an approved US drug, there is no official US label dose, and there is no validated dose for self-use. We report numbers strictly as 'studied at X in [population] by [route].' If you take one thing from this page, take the route and the timescale, not a number to copy.
Thymosin alpha 1 dosage
Thymosin alpha 1 dosage in the literature centers on a small subcutaneous dose. A comprehensive review reports a standard single subcutaneous dose ranging from 0.8 to 6.4 mg, with multiple-dose regimens of 1.6-16 mg over five to seven days [6]. The most-cited chronic regimen, used for hepatitis B and C, is 1.6 mg subcutaneous twice weekly - the thymalfasin label-equivalent schedule documented in the pharmacology monograph [4]. These are reported as study and approved-abroad parameters, not recommendations. There is no FDA-approved US dose, because the drug is not approved for US marketing [6].
Doses by setting, as studied
Across indications the dose tracks the urgency of the setting. In the sepsis RCTs ETASS and TESTS, the protocol was 1.6 mg subcutaneous every 12 hours for five to seven days [2][3]. COVID-19 cohort studies used 1.6 mg subcutaneous daily [6]. Cancer combination protocols typically used 1.6 mg subcutaneous twice weekly, and one non-small-cell-lung-cancer chemoradiotherapy-adjunct study used weekly subcutaneous injection for up to 12 months [7]. Every one of these is a study parameter attached to a specific population - not a template for anyone to follow. The consistent thread is the subcutaneous route and a milligram-scale dose.
Half-life and pharmacokinetics
Thymosin Alpha-1 does not stick around. Human pharmacokinetic work describes an elimination half-life of roughly 2 hours after subcutaneous injection, with peak levels at about 1-2 hours and blood concentrations returning toward baseline within about 24 hours; its volume of distribution is consistent with distribution into extracellular fluid. An in vitro characterization study measured a plasma half-life of approximately 127 +/- 11 minutes and described engineering a Thymosin Alpha-1-thymopentin fusion peptide intended to extend stability beyond the parent peptides [12]. The peptide is highly acidic (isoelectric point about 4.2), does not extensively bind plasma proteins, and is degraded by tissue and circulating aminopeptidases, which is why it is supplied lyophilized (freeze-dried) and why the N-terminal acetylation that protects its activity matters [12].
Routes and formulation notes
Subcutaneous injection is the primary clinical route in essentially all trials; mechanistic studies used in vitro and ex vivo systems, and preclinical work used in vivo murine models [6]. Researchers have also tried to engineer around the short half-life: a pharmaceutical-technology study prepared PLGA-based injectable sustained-release Thymosin Alpha-1 microspheres that achieved roughly 90% cumulative release over one month in vitro and increased the CD4+/CD8+ ratio in immunosuppressed rats [13]. None of this changes the bottom line for a reader: there is no approved US product, no validated self-use dose, and the only honest dosing content is third-person and study-attributed.